Currently, engineered a non-pathogenic E. coli strain, expressing encoded nanobody antagonist of CD47, or nanobodies targeting PD-L1 and CTLA4, or STING agonist, were administered to activate systemic antitumor immunity and to regress tumor burden in mouse models (118–120), although, until now, those engineered probiotics were designed to kill tumors, directly. The gene discussed is STING1; the disease is neoplasm.